The finding that KRAS inhibition augments RIG-I-induced immune responses underscores an interplay between oncogene silencing and innate immune activation, highlighting the translational potential of this combination therapy for KRAS-mutated cancers resistant to conventional treatments. This evidence concerns the gene RIGI and cancer.